This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
Retraction: Abdallah MS, Mosalam EM, Hassan A, et al. Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double‐blind, randomized, placebo‐controlled trial. CNS Neurosci. Ther. 2023;29:354–364 (https://doi.org/10.1111/cns.14010)
TL;DR
This paper is a retraction of a study on using pentoxifylline to treat schizophrenia symptoms, due to concerns about data integrity.
Contribution
The paper formally retracts a prior clinical trial, highlighting issues with data reliability and research integrity.
Findings
The clinical trial's data was found to be unreliable.
The retraction was agreed upon by the Editor-in-Chief and publisher.
Confidence in the study's results was lost after an investigation.
Abstract
Retraction: Abdallah MS, Mosalam EM, Hassan A, et al. Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double‐blind, randomized, placebo‐controlled trial. CNS Neurosci. Ther. 2023;29:354–364 (https://doi.org/10.1111/cns.14010) The above article, published online on November 07, 2022 in Wiley Online Library (wileyonlinelibrary.com) has been retracted by agreement between the journal's Editor‐in‐Chief, Xiaoming Hu, and John Wiley and Sons Ltd. Following publication, the Editor‐in‐Chief raised concerns about the integrity of the clinical trial. An investigation revealed significant issues regarding the reliability of the reported data. As a result, the Editor‐in‐Chief no longer has confidence in the validity of the results presented in this article.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHealth Systems, Economic Evaluations, Quality of Life · Schizophrenia research and treatment · Tryptophan and brain disorders
Retraction: Abdallah MS, Mosalam EM, Hassan A, et al. Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double‐blind, randomized, placebo‐controlled trial. CNS Neurosci. Ther. 2023;29:354–364 (https://doi.org/10.1111/cns.14010)
The above article, published online on November 07, 2022 in Wiley Online Library (wileyonlinelibrary.com) has been retracted by agreement between the journal's Editor‐in‐Chief, Xiaoming Hu, and John Wiley and Sons Ltd. Following publication, the Editor‐in‐Chief raised concerns about the integrity of the clinical trial. An investigation revealed significant issues regarding the reliability of the reported data. As a result, the Editor‐in‐Chief no longer has confidence in the validity of the results presented in this article.